Login
$ETON
$63.88 -$0.05 (0.08%) Live

Company Executives

Officer Age In this role 2025 pay Source
Sean E. Brynjelsen Also a director
President, Chief Executive Officer and Director
54 Since 2017
9 years
$2,914,489
James R. Gruber
Chief Financial Officer, Treasurer, and Secretary
54 Since 2022
4 years
$1,398,068
Judith M. Matthews
Chief Financial Officer
Title from the Form 4 dated Jul 31, 2026
Not stated Not stated Not reported
Danka Radosavljevic
Chief Operating Officer
Title from the Form 8-K dated Jul 31, 2026
Not stated Not stated Not reported
David C. Krempa
Chief Business Officer
37 Since 2023
3 years
$1,394,745
Ipek Erdogan-Trinkaus
Chief Commercial Officer
44 Since 2024
2 years
$575,292

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
5
serving now
Independent
0 of 1
stated in the proxy; 4 not stated
Average tenure
8.2 years
from year joined
CEO also chairs the board
No
Norbert G. Riedel
Director On board Independent Committees Other public boards 2025 pay Source
Norbert G. Riedel
2017
9 years
Not stated
audit nominating and corporate governance · Chair
Jazz Pharmaceuticals Not stated
Sean E. Brynjelsen
2017
9 years
Not independent None stated None stated Paid as CEO
Jenn Adams
2021
5 years
Not stated
audit nominating and corporate governance
None stated $267,027
Charles J. Casamento
2017
9 years
Not stated
audit nominating and corporate governance
PaxMedica, Relmada Therapeutics, GT Biopharma $275,139
Paul V. Maier
2017
9 years
Not stated
nominating and corporate governance
International Stem Cell Corporation $277,843

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

2 disclosed in the proxy filed Apr 24, 2026
Selenix LLC
an entity affiliated with our Chief Executive Officer
Amount not stated
2024 and 2025

Amended asset purchase agreement for DS-200 under which Selenix waived milestone payments and 50% of DS-200 profit in exchange for 45% of DS-200 sale proceeds; Company made payments to Selenix

With the Company Open in proxy
Skye Cooper
daughter of our Chief Executive Officer
$238,180
2025

Employment with the Company; total compensation received

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support